💸 The Tape

Canopy Growth announced last week that its Kincardine, Ontario cultivation facility has had its EU GMP certification renewed by the Regierungspräsidium Tübingen in Baden-Württemberg. On the surface this is housekeeping — a renewal, not a first-time approval, the regulatory equivalent of remembering to renew your passport before the trip. But the timing is doing more work than the press release admits, because the European import market is quietly sorting itself into two tiers, and the sort is about to get a lot less quiet.

Canopy's framing is worth noting: Kincardine is the anchor asset of an end-to-end EU GMP flower supply chain, running Canadian-cultivated flower into its second EU GMP facility at Sankt Leon-Rot, Germany. That's cultivation-side GMP connected to distribution-side GMP with no third-party toll processor in the middle. Management pointed to a 10% year-over-year increase in international cannabis net revenue in Q1 fiscal 2027 and flagged incoming MTL Cannabis genetics to broaden the flower portfolio. Modest growth, but growth in the right column.

Where the Other Two Stand

SNDL is the newest entrant to this conversation and is not quite there yet. On August 4, 2026, the company announced successful completion of an EU-GMP audit at its Atholville, New Brunswick facility, with certification anticipated within 90 days of the audit. That puts a certificate in hand somewhere around early November, assuming no findings require remediation. The asset is meaningful: roughly 380,000 square feet, more than 110,000 square feet of canopy, and production supporting approximately 4,500 kilograms per quarter, with company commentary suggesting capacity beyond 30 tonnes given additional investment.

The distinction matters and gets flattened constantly in coverage. Passing an audit is not holding a certificate. SNDL is in the waiting room. It is a good waiting room, but nobody ships against it.

Village Farms has been holding this card since March 2022, when Pure Sunfarms received EU GMP certification from Bezirksregierung Düsseldorf for its 1.1 million square foot Delta 3 facility in British Columbia. The company now describes its Delta campus as the world's largest EU-GMP certified cannabis facility and exports to Germany, the UK, Israel, Australia and New Zealand. The Delta 2 conversion is adding roughly 40 metric tonnes of annual capacity in phases through the first half of next year.

So the board looks like this: Village Farms with four years of certified operating history and the largest certified footprint, Canopy with a renewed cultivation certificate plus German-side GMP, and SNDL with a large asset and a pending certificate.

The Greenwashing Question

Here's the part the sell-side decks tend to skip. Germany's import framework requires GACP at cultivation and EU GMP at the manufacturing level. Those are two different steps, and — critically — they do not have to happen in the same country, or at the same company.

Which is how a great deal of flower reaches German pharmacy shelves. Grow to GACP standard somewhere with cheap inputs. Ship it to a third-country EU GMP processor — Portugal is the dominant hub, which is precisely why it sits second behind Canada in German import volume — where it gets processed, packaged and batch-released. It arrives in Germany carrying a GMP release, and the patient, the pharmacist and often the prescriber read that as a statement about how the plant was grown.

It isn't. It's a statement about how the plant was handled after it was grown.

This is not fraud. It's the framework working as designed. But it produces a quality inference that the paperwork doesn't actually support, and the scale is not trivial. Germany imported 201,094 kg of medical cannabis flower in 2025, with Canada supplying roughly 93,006 kg, about 46%. Q1 2026 came in at 50,539 kg, pushing the rolling twelve-month total past 218 tonnes, with Canada's share strengthening toward 53%. Somewhere inside those numbers is a meaningful volume of product whose GMP credential attaches to a packaging line in southern Europe rather than a grow room.

Do the Incumbents Take It Back?

The economic case for vertically certified operators is straightforward. Every handoff to a toll processor is margin surrendered, time added to batch release, and a hole in the chain of custody where accountability gets fuzzy. Cultivation-site GMP collapses that. And the barrier is real: standing up EU GMP capacity runs roughly €2.5 million to €11 million and takes 18 to 36 months. That's not a moat you cross on enthusiasm.

The case against is one word: price. Germany is a pharmacy-dispensed, price-compressed market, and toll-processed GACP flower is cheaper. Quality premiums only get paid when someone is forced to pay them.

Which brings us to the actual catalyst. The MedCanG amendment — banning telemedicine-only prescriptions and mail-order dispensing — was adopted by the Federal Cabinet on October 8, 2025 and passed its first Bundestag reading on December 18, 2025. It has not advanced to second and third readings and is not in force, with SPD parliamentarians publicly resisting the most restrictive provisions. But the telemedicine channel is exactly what created the demand spike that pulled marginal supply into Germany in the first place.

The Conclusion Worth Underlining

If the MedCanG amendment lands in anything close to its current form, the greenwashed tier gets flushed first — not because regulators target it, but because it was always the marginal supply serving the marginal patient. Contract the demand base and the cheapest, least-differentiated kilos are the ones that stop clearing. Vertically certified operators with existing German distribution absorb what remains.

A year from now, my expectation is a German import market that is flat to modestly smaller in tonnage but materially higher in average quality — and, more importantly, one where "EU GMP" stops functioning as a binary marketing checkbox and starts getting parsed by where in the chain the certification actually sits. Expect importers and pharmacy groups to begin asking for cultivation-site GMP specifically. Expect the operators who have it to start saying so loudly.

Village Farms has the longest runway and the biggest certified footprint. Canopy has the cleanest end-to-end story on paper and now needs volume to make it matter. SNDL has the asset and needs the certificate to land clean in November.

The differentiator was never the certificate. It was always which step it covers — and the market is finally about to start reading the fine print.

📈 Dog Walkers

$HELP ( ▲ 4.72% ) Reports Q1

Helus Pharma (Nasdaq: HELP) closed its June quarter with the two things a clinical-stage company most wants going into a readout: an enrolled pivotal trial and a bank balance that outlives it.

The headline is completed enrollment in APPROACH, the Phase 3 pivotal study of HLP003 in major depressive disorder, with topline data on track for Q4 2026. That is the whole equity story now sitting on a single date. Second pivotal study EMBRACE continues enrolling, and participants are rolling into EXTEND for long-term durability and redosing data.

New leadership arrives for the occasion. Michael Halstead, formerly President of Intra-Cellular Therapies, takes the CEO seat — a commercial CNS pedigree rather than a discovery one, which tells you what stage the board thinks the company is entering.

The quietly important item is the drug-drug interaction study. HLP003 showed no meaningful effect on plasma levels across six substrates tested, indicating no PK interaction with the CYP450 enzymes examined. Combined with the literature, that supports low DDI risk against SSRIs and SNRIs — which matters enormously, because the realistic commercial path for a novel serotonergic agonist in MDD is adjunctive, layered onto patients already medicated. Clean DDI data is what makes that label plausible.

The Phase 2 numbers are the sort that get screenshotted: roughly a 23-point MADRS reduction at 12 months following two 16 mg doses three weeks apart, with 100% response and 71% remission against a ≤10 remission benchmark. Read those with discipline. They are small-population, within-subject figures without the placebo control that makes psychiatric endpoints so notoriously humbling. Placebo response in MDD trials eats spectacular open-label results for breakfast. APPROACH exists precisely to find out.

HLP004 in generalized anxiety disorder looks like the more interesting asset commercially — a roughly 10-point HAM-A improvement on top of standard of care at six weeks, acute effects lasting about 90 minutes, and 100% of Phase 1 participants discharge-ready within three hours. A short-acting agent that doesn't require a full-day monitored session is a fundamentally different reimbursement conversation. Next study design lands by end of Q3 2026.

Financially: $166.4 million in cash after a $50 million June raise, against $37.1 million in quarterly operating cash burn — call it four to five quarters of runway. Net loss widened to $47.8 million from $24.6 million. That burn is Phase 3 doing what Phase 3 does.

Bottom line: funded through the catalyst, with no need to raise into it. Everything now rides on Q4.

📺 Trade To Black

Cannabis Rescheduling Enters New Phase Next Week | TDR Cannabis in 5

• Monday, August 17 is the filing-brief deadline in the ALJ rescheduling hearing — testimony is complete, evidence is closed, and the process now shifts from public proceedings to the judge drafting his Recommended Decision behind closed doors.

• TerrAscend (TSX: TSND) was served in DOJ's 280E tax case on August 3 — more than two months after filing, and two weeks before the ALJ deadline. Service timing is rarely accidental in federal practice, and the overlap with the rescheduling calendar has the industry reading it as strategic positioning.

• The calendars converge: TerrAscend's response is due August 24, DOJ's reply lands in September, and the ALJ's recommendation could arrive in the same window. A shortened exceptions period would start DEA's fixed 30-day Final Order clock in September — putting a potential decision in October.

• The stakes are binary. Schedule III eliminates 280E, rendering the TerrAscend case moot. Monday isn't the decision — it's the trigger that starts the countdown toward DEA's final ruling.